In particular, with regard to the overexpression of the kidney isozyme of glutaminase, GLS1, in a large number of cancers28, 29 including PDAC, a number of GLS1 inhibitors, including CB‐839 and BPTES‐NP, have been developed and CB‐839 has even reached clinical trials.5 The clinical efficacy, however, shows opportunities for improvement in regards to tumor reduction. Here, GLS is linked to neoplasm.